Experimental drug targets rare blood cancer in patients out of options
NCT ID NCT03011372
Summary
This study tested an experimental drug called pemigatinib in 47 patients with rare blood cancers caused by a specific genetic change (FGFR1 rearrangement). These patients had either relapsed after previous treatments like stem cell transplants or weren't candidates for those treatments. Researchers measured how well the drug controlled the cancer and monitored side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MPN (MYELOPROLIFERATIVE NEOPLASMS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Azienda Ospedaliero-Universitaria Careggi (Aouc)
Florence, 50134, Italy
-
Centre Leon Berard
Lyon, 69373, France
-
Chu de Nice - Hospital L Archet
Nice, 06202, France
-
City of Hope National Medical Center
Duarte, California, 91010, United States
-
Emory University - Winship Cancer Institute
Atlanta, Georgia, 30322, United States
-
Franciscan St. Francis Health
Indianapolis, Indiana, 46237, United States
-
Guys and St Thomas Nhs Foundation Trust
London, SE1 9RT, United Kingdom
-
Hospital Clinico Universitario de Valencia
Valencia, 46010, Spain
-
Hospital Saint Louis
Paris, 75475, France
-
Iii Med. Abteilung For Hematologie and Onkologie Hanuscfhkrankenhaus
Vienna, 01140, Austria
-
Inselspital - Universitaetsspital Bern
Bern, 03010, Switzerland
-
Johannes Wesling Klinikum Minden
Minden, 32429, Germany
-
Kindai University Hospital
Osaka, 589-8511, Japan
-
Mayo Clinic Arizona
Phoenix, Arizona, 85054, United States
-
Md Anderson Cancer Center
Houston, Texas, 77030, United States
-
Medical University of Vienna
Vienna, 01090, Austria
-
Ntt Medical Center Tokyo
Tokyo, 141-8625, Japan
-
Ordensklinikum Krankenhaus Der Barmherzigen Schwestern Linz
Linz, 04010, Austria
-
Ospedale Papa Giovanni Xxiii
Bergamo, 24127, Italy
-
Oxford University Hospitals Nhs Foundation Trust
Oxford, OX3 7LE, United Kingdom
-
Princess Margaret Cancer Center
Toronto, Ontario, M5G 2M9, Canada
-
Stanford Cancer Institute
Stanford, California, 94305, United States
-
Universitair Ziekenhuis (Uz) Leuven
Leuven, 03000, Belgium
-
Universitaire Du Cancer de Toulouse Institut Claudius Regaud Iuct-Oncopole
Toulouse, 31059, France
-
Universitatsklinikum Halle (Saale)
Halle, 06120, Germany
-
Universitatsklinikum Jena
Jena, 07740, Germany
-
Universitatsklinikum Leipzig
Leipzig, 04103, Germany
-
Universitatsspital Zurich
Zurich, 08091, Switzerland
-
University Hospital Mannheim
Mannheim, 68167, Germany
-
University Medical Center Rwth Aachen
Aachen, D-52074, Germany
-
University of Utah
Salt Lake City, Utah, 84112, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
-
Weill Cornell Medical Centers
New York, New York, 10021, United States
Conditions
Explore the condition pages connected to this study.